drugset / Trial / NCT01551446

Pilot Assessment of the Effects of Bardoxolone Methyl on Renal Perfusion, Systemic Haemodynamics and Cardiac Function in Patients With Chronic Kidney Disease and Type 2 Diabetes

NCT01551446 ↗

Phase 1 Withdrawn Biogen
NaSingle-groupOpen-labelTreatment

Summary

This study is to evaluate the variability of several pharmacodynamic measures of kidney function, cardiovascular function, cerebral perfusion, and haemodynamics.

Timeline

Start
2012-04-30
Primary completion
2012-11-30
Completion
2012-11-30

Outcome

Outcome not reported

Stopped: “IDMC recommendation for safety concerns”

Drugs

EvaluationDrugModalityDoseRoute
Subject Bardoxolone methyl Small molecule 20 mg Oral